CLL-1 has emerged as a possible target for antibody-mediated immunotherapy in AML and presents more precise and effective diagnosis and treatment options (Shin et al., 2022; Daver et al., 2021; Tashiro et al., 2017). Here, CLEC12A is linked to acute myeloid leukemia.